companiesCompany
Nippon Kayaku
aka Nippon Kayaku Co., Ltd., 日本化薬
Nippon Kayaku is a Japanese chemicals and pharmaceuticals group whose medicines business specialises in cancer: generic chemotherapy, supportive care products and biosimilars of antibodies such as trastuzumab for the Japanese market.
Overview
Nippon Kayaku, listed in Tokyo, is a diversified chemicals company whose pharmaceutical division concentrates on oncology in Japan, supplying generic cytotoxic drugs, supportive care medicines and biosimilar antibodies including a trastuzumab biosimilar, and running the domestic phase 3 trials that biosimilar approval in Japan requires. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Tokyo, JP
Scorecard
All companies#64of 832 companies, score 47
- approved products +6
- targets +2
- modalities +2
- regions +7
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 1,211 registry studies. Formula on the scorecards page.
Type
pharma
Stage
Public